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Objectives: To investigate the long-term effect of continuous insulin infusion for glucose 
control on cerebral metabolism in aneurysmal subarachnoid hemorrhage (SAH) patients.
Methods: Prospective, nonrandomized study of 31 SAH patients in the ICU (52 ± 10 years, 
WFNS Grade 2.9 ± 1.6). A microdialysis catheter was inserted into the vascular territory of the 
aneurysm. Metabolic changes during 4 days after onset of insulin infusion were analyzed. Blood 
glucose levels 140 mg/dL after clinical stabilization were treated with intravenous insulin.
Results: 24 patients were treated with intravenous insulin. Though no insulin-induced hypo-
glycemia occurred, cerebral glucose decreased on days 1–4 after insulin onset without reaching 
critical levels. Glycerol, a marker of membrane degradation, showed a reversible increase on 
day 1 while the lactate/pyruvate ratio remained stable and glutamate even decreased indicating 
absence of severe cerebral crisis following insulin infusion and excluding ischemia as a cause 
for cerebral glucose depletion.
Conclusions: Concerning cerebral metabolism, long-term continuous insulin infusion appears 
to be safe as long as cerebral glucose levels do not fall below the physiological range. In view 
of the high incidence of hyperglycemia and need for insulin treatment, future studies on the 
effect of insulin on cerebral metabolism in SAH patients are desirable.
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Introduction
Hyperglycemia has been shown to increase infarct volume and neurological deﬁ  cits in 
many experimental models of cerebral hypoxic-ischemic injury (Ginsberg et al 1980; 
D’Alecy et al 1986). Clinical studies also indicate an adverse effect on outcome when 
cerebral ischemia occurs in the setting of hyperglycemia (Pulsinelli et al 1983). In acute 
stroke and aneurysmal subarachnoid hemorrhage (SAH), mortality rates are increased 
if fasting plasma glucose concentrations exceed 6.1 mmol/L (110 mg/dl) (Candelise 
et al 1985; Badjatia et al 2005; Frontera et al 2006). These ﬁ  ndings suggest that even 
mild hyperglycemia, induced both exogenously or endogenously, signiﬁ  cantly impairs 
neurological post-ischemic outcome.
Cerebral microdialysis (MD), an established neuromonitoring technique analyz-
ing cerebral extracellular ﬂ  uid, can measures glucose, the main source of energy to 
the brain, and its metabolites online in the neurointensive care unit (Ungerstedt 1991; 
Hutchinson et al 2002; Sarrafzadeh et al 2002). In traumatic brain injury (TBI) patients, 
low cerebral glucose was associated with unfavorable outcome (Vespa et al 2003), and 
in SAH with a severe metabolic derangement (Schlenk et al 2008b). Targeted insulin 
therapy for glycemic control induced a decrease in cerebral glucose and an increase 
in markers of cerebral ischemia in TBI patients (Vespa et al 2006). In SAH patients, 
insulin treatment did not show evidence of clinical deterioration (Bell et al 2005), but 
induced mild cerebral glucose depletion in the ﬁ  rst hours of infusion (Schlenk et al 
2008a). However, lacking respective data on the long-term effects of insulin on cerebral Vascular Health and Risk Management 2008:4(4) 886
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metabolism in SAH patients, the purpose of this study was to 
investigate the potentially harmful effect of insulin treatment 
on cerebral metabolism in SAH patients.
Clinical material and methods
Patient characteristics and management
This study was approved by the Local Research Ethics Com-
mittee at Charité Virchow Medical Center, in accordance 
with the Declaration of Helsinki as revised in Edinburgh in 
October 2000, and is part of an ongoing prospective study 
on cerebral metabolism monitored by bedside microdialysis 
in aneurysmal SAH patients.
Thirty-one consecutive patients were enrolled who were 
admitted to the neurosurgical department of a university 
hospital between August 2005 and June 2007 and met the 
following criteria: 1) SAH conﬁ  rmed by head computerized 
tomography (CT); 2) cerebral angiogram demonstrating 
intracranial aneurysm(s); 3) surgical therapy or endovascular 
therapy in combination with ventricular drainage. Exclusion 
criteria were hemodynamic instability, ﬁ  xed and dilated 
pupils on admission, death within 24 hrs after admission and 
endovascular therapy of the posterior cerebral circulation.
All patients considered surgical candidates were man-
aged according to a uniform protocol detailed previously 
(Sarrafzadeh et al 2002). Depending on their neurological 
course, the patients were classiﬁ  ed as asymptomatic patients 
(n = 6) and patients presenting acute focal (AFND, n = 14) 
or delayed ischemic neurological deﬁ  cits (DIND, n = 11), 
with detailed deﬁ  nitions described previously (Sarrafzadeh 
et al 2002). In case of any neurological deterioration, a CT 
was performed to rule out hydrocephalus, infarction, or 
rebleeding/intracerebral hemorrhage as possible causes of 
deterioration.
Glucose levels were targeted to be 7.8 mmol/L 
(140 mg/dL) using continuous intravenous regular insulin 
if necessary. Routine glycemic control consisted of blood 
glucose checks every 4 hrs (6 hrs in patients without insulin 
treatment) and insulin infusion starting at a ﬂ  ow rate of 2 ml/h 
(with 1 ml = 1 IE) and adjusted by the bedside nurse according 
to the actual blood glucose level (maximum 8 ml/h). In patients 
with instable glucose levels, blood glucose was checked every 
1 to 3 hrs. Global handicap was assessed using the Glasgow 
Outcome Scale (GOS) at 3 months (Jennett et al 1975).
Bedside microdialysis
A microdialysis catheter (CMA 70, CMA Microdialysis, 
Solna, Sweden; length 10 mm, molecular weight limit of 
100.000 Dalton) was inserted immediately after aneurysm 
clipping or with placement of a ventricular drainage into 
brain parenchyma of the corresponding vascular territory of 
the aneurysm, eg, the right frontal lobe in patients with an 
anterior communicating artery aneurysm. Care was taken to 
avoid insertion into macroscopically lesioned brain tissue or 
into an intracerebral hemorrhage. Catheters were perfused 
with sterile Ringer’s solution at a ﬂ  ow rate of 0.3 μL/min. 
On the outlet tube perfusates were collected in microvials, 
exchanged hourly and analyzed immediately at bedside in 
a mobile photometric, enzyme-kinetic analyzer (CMA 600, 
CMA Microdialysis, Solna, Sweden). The estimated recov-
ery for the system is 0.65–0.72 (Hutchinson et al 2000b). 
Parameters of energy metabolism (glucose, pyruvate, lactate, 
lactate/pyruvate ratio), glycerol (a marker of membrane 
degradation) and glutamate (a marker of ischemia) were 
analyzed (Ungerstedt 1991; Saveland et al 1996; Hutchinson 
et al 2000a). MD data are presented as daily medians calcu-
lated from hourly measured microdialysate concentrations. 
A critical decrease in cerebral glucose was deﬁ  ned as a 
decrease below 0.6 mmol/L, corresponding to the mean level 
minus 1 standard deviation of our SAH patients without any 
neurological symptoms (Schlenk et al 2008b).
Data analysis
All data were collected during days 1–10 after admission 
due to SAH. Between-group comparisons were performed 
using Kruskal-Wallis one-way analysis of variance. Statisti-
cal analysis of not normally distributed sequential data over 
time was performed using Wilcoxon signed-rank test. Data 
in the tables and text are expressed as mean ± standard devia-
tion if not speciﬁ  ed otherwise. Differences were considered 
statistically signiﬁ  cant at p  0.05. All statistics were done 
using SPSS 14.0 (SPSS Inc., Chicago, IL, USA).
Results
Demographic and clinical characteristics of the 31 patients 
are summarized in Table 1. Patients were classiﬁ  ed into a 
noninsulin-treatment group (n = 7) and an insulin-treatment 
group (n = 24) (Table 1).
Blood glucose and insulin treatment
After stabilization on day 1 after SAH, insulin treatment was 
necessary in 24 patients. Median blood glucose on the day 
of onset of insulin infusion was 7.9 ± 0.8 mmol/L (141.5 ± 
14.7 mg/dL). No insulin-induced hypoglycemia occurred 
within 10 days after SAH.
Cerebral vasospasm as an insulin-independent cause for 
the observed glucose depletion can widely be excluded as Vascular Health and Risk Management 2008:4(4) 887
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insulin infusion started before onset of DIND in almost all 
DIND patients.
Long-term effect of insulin 
on cerebral metabolism
As recently a decrease in cerebral glucose and a trend to 
elevated glycerol levels within the ﬁ  rst 12 hours after onset 
of insulin infusion were observed, we performed this analysis 
to study the long-term effects of insulin (Schlenk et al 2008a). 
Microdialysis parameters were analyzed daily for 4 days 
after onset of insulin infusion. Blood glucose remained stable 
after insulin onset, and no hypoglycemia occurred. Cerebral 
glucose decreased on days 1 to 4 after insulin onset, however 
it did not reach critically low levels (p = 0.009; Figure 1).
Glycerol, a marker of cellular membrane degradation, 
increased until day 1 after insulin onset (p = 0.049) and 
then decreased again reaching baseline levels on day 4 after 
onset of insulin infusion (Figure 2A). The lactate/pyruvate 
ratio (LPR), a marker of anaerobic metabolism, remained 
stable indicating absence of cellular distress (Figure 2B). 
Interestingly, extracellular concentrations of glutamate 
decreased during insulin infusion (p  0.05), indicating that 
no ischemia or relevant neuronal damage was present during 
the observation period (Figure 2C).
Discussion
There are two principal ﬁ  ndings of this study. First, though 
no insulin-induced hypoglycemia occurred, cerebral glucose 
decreased on days 1–4 after insulin onset, however without 
reaching critical levels. Second, median daily concentrations 
of glycerol as a marker of cellular membrane degradation 
showed an increase one day after insulin onset, returning to 
baseline on day 4.
In hours 9–12 of insulin infusion, a trend to a glycerol 
increase of unclear relevance had been observed previously 
(Schlenk et al 2008a). Regarding the long-term course, these 
glycerol changes might indicate a mild transient metabolic 
derangement following insulin infusion. However, the LPR 
remained stable and glutamate, a marker of neuronal injury 
and ischemia, decreased excluding ischemia as a relevant 
cause of cerebral glucose depletion and, even more impor-
tant, indicating no substantial neuronal damage. Together, 
this pattern might be interpreted as absence of a relevant 
and continuous metabolic crisis following long-term insulin 
infusion, as long as cerebral glucose levels remain within the 
physiological range.
Hyperglycemia
Hyperglycemia at the time of brain injury, such as ischemic 
stroke or brain trauma, is known to be associated with 
increased morbidity and mortality (Walia et al 2002; Bhalla 
et al 2003). Persistence of hyperglycemia during the post-
stroke episode was found to be independently associated with 
infarct expansion and adverse outcome (Baird et al 2003). 
Preventive glycemic control with levels not substantially 
exceeding 6.1 mmol/L (110 mg/dL) reduced mortality dur-
ing intensive care by more than 40% (van den Berghe et al 
2001). Nevertheless, thresholds for glucose levels to be 
treated with insulin vary considerably for SAH patients (van 
den Berghe et al 2001; Badjatia et al 2005; Frontera et al 
2006). Since hyperglycemia appears to be injurious in brain 
ischemia conditions, avoidance of hyperglycemia should 
be a general strategy in treatment of SAH (Lanzino et al 
Table 1 Characteristics of 31 SAH patients. Data are expressed as mean ± SD or absolute numbers and percentage, p values are given 
for between-group comparison of insulin-treated and not insulin-treated patients (Kruskal-Wallis one-way analysis of variance)
 Treatment  groups    p
  Insulin treatment (n = 24)  No insulin treatment (n = 7) 
Age (years)  54.0 ± 9.5  46.0 ± 8.7  0.04
Gender: male/female  7/17  1/6  0.44
Neurological symptoms:     
Asymptomatic/AFND/DIND 1/14/9  5/0/2  0.03
WFNS score  3.3 ± 1.6  1.6 ± 0.8  0.02
I (%), II (%), III (%)  5 (21), 4 (17), 2 (8)  4 (57), 2 (29), 1 (14) 
IV (%), V (%)  6 (25), 7 (29)  0, 0 
Fisher score  3.7 ± 0.6  3.2 ± 0.8  0.06
Time SAH – surgery (hrs)  14.5 ± 7.8  15.4 ± 7.9  0.72
GOS after 3 months  3.13 ± 1.62  4.83 ± 0.41  0.02
Abbreviations: WFNS, World Federation of Neurological Surgeons Grading of SAH (Drake 1988);  AFND, acute focal neurological deﬁ  cit; DIND, delayed ischemic neurological 
deﬁ  cit; SAH, subarachnoid hemorrhage; GOS, Glasgow Outcome Scale (Jennett et al 1975).Vascular Health and Risk Management 2008:4(4) 888
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1993; Scott et al 1999; Sarrafzadeh et al 2004; Badjatia et al 
2005; Frontera et al 2006). However, the cause-effect rela-
tionship between hyperglycemia and unfavorable outcome 
remains controversial as hyperglycemia might either occur 
stress-related and reﬂ  ect – as a symptom – the severity of 
the primary injury, or act as a secondary force deteriorating 
brain damage and thereby contributing to adverse outcome. 
Furthermore, postulating an intact blood-brain barrier, high 
blood glucose does not necessarily imply high cerebral 
glucose levels. Several glucose transport proteins (GLUT) 
are involved in the delivery of glucose from the circulation 
to the brain, such as GLUT1 in glia and the microvascular 
endothelial cells forming the blood-brain barrier, and GLUT3 
in neurons (Hamlin et al 2001).
Our results, though limited by various factors, indicate 
a signiﬁ  cant insulin-related decrease in cerebral glucose 
levels though blood glucose remained stable. This lack of a 
signiﬁ  cant decrease in blood glucose might be attributed to 
diverse factors such as catecholamines (either endogenous or 
iatrogenic administered) or the loose protocol for glycemic 
control rather accepting marginally elevated glucose levels 
than inducing hypoglycemia.
Since cerebral glucose remained within the physiological 
range even after the observed decrease, the complete recovery 
of the initial glycerol elevation and the lack of deterioration 
in the other markers of metabolic crisis (LPR and glutamate) 
are consistent. Future studies might detect relevant metabolic 
derangements when insulin is administered to patients with 
cerebral glucose levels already lowered in a critical way.
Insulin and cerebral metabolism
The debate about the role of insulin in cerebral glucose 
metabolism has not been resolved. In-vitro and experimental 
data demonstrated that insulin can penetrate the blood-brain 
barrier and enter the brain (Steffens et al 1988). The proof 
of insulin receptors in neuronal tissue raises the question 
of their functional signiﬁ  cance (Kenner et al 1995). Recent 
data give evidence that physiologic levels of circulating 
insulin do not affect brain glucose uptake and that cere-
bral glucose uptake and metabolism is predominantly an 
Figure 1 Course of plasma and cerebral glucose before and during insulin infusion. Data are expressed as mean ± standard error of daily median values measured in 24 
patients treated with continuous intravenous insulin. Levels of signiﬁ  cance are indicated for comparison with glucose values on the day of insulin onset (Wilcoxon signed-
rank test).
Notes: *p  0.05, (*)p  0.08.Vascular Health and Risk Management 2008:4(4) 889
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insulin-independent process in humans (Cranston et al 1998; 
Seaquist et al 2001). Nevertheless, data from TBI patients 
support the concern that a reduction in serum glucose could 
create substrate limitation in the injured brain (Vespa et al 
2006). In the present study, insulin treatment appeared to be 
safe as median cerebral glucose concentrations did not fall 
below a critical threshold during insulin infusion. However, 
it is unclear whether insulin can be recommended in patients 
with low intracerebral glucose levels which might decrease 
further to critically low levels and compromise cerebral 
energy metabolism substantially. Therefore, in our view the 
monitoring of cerebral glucose especially at onset of and dur-
ing insulin treatment is valuable in SAH patients. This might 
be relevant as a correlation between low cerebral glucose 
levels (0.2 mmol/L) and unfavorable outcome could be 
shown in TBI patients (Vespa et al 2003).
Current approaches for glycemic 
control in SAH
The strategy of insulin treatment in this study was to rather 
tolerate marginally elevated blood glucose levels than to 
induce hypoglycemia. With the applied blood glucose target 
range (4.4–7.8 mmol/L; 80–140 mg/dL), no hypoglycemia 
but frequent hyperglycemia was observed. In a much-noticed 
publication on glucose control in critically ill patients, Van 
den Berghe suggests blood glucose levels between 4.4 and 
6.1 mmol/L (80–110 mg/dL), referring to data from cardiac 
surgery patients (van den Berghe et al 2001). A more recent 
publication, studying 63 patients with brain lesions (includ-
ing brain tumors) demonstrated that intensive insulin therapy 
with blood glucose levels 6.1 mmol/L (110 mg/dL) 
shortened intensive care dependency and reduced intracranial 
pressure as well as the need for vasopressors for maintaining 
adequate cerebral perfusion pressure (Van den Berghe et al 
2005). It is questionable if these thresholds are applicable 
for patients with possibly compromised cerebral metabolism 
and regionally increased cerebral energy demand as described 
in aneurysmal SAH. Recently, the effect of intensive insulin 
therapy (4.4–6.7 mmol/L vs 4.4–12.2 mmol/L; 80–120 mg/dL 
vs 80–220 mg/dL) was studied in 78 aneurysmal SAH 
patients, revealing that infection rates could be lowered 
by strict glycemic control, while a beneﬁ  t concerning the 
incidence of DIND, outcome, and mortality was not found 
(Bilotta et al 2007).
Limitations of this study
The small and heterogenous study groups limit the conclu-
sions that can be drawn concerning the effects of insulin, 
especially as patients with more severe hemorrhage are pre-
dominantly found in the insulin-treatment group. However, 
this was unavoidable as it seems not justiﬁ  able to exclude 
hyperglycemic patients from insulin treatment considering 
the strong evidence for an association between hyperglycemia 
Figure 2 Course of markers of cerebral distress before and during insulin infusion. 
(A) Glycerol, (B) Lactate/pyruvate ratio, (C) Glutamate. Data are expressed as mean ± 
standard error of daily median values calculated from hourly measured microdialysate 
concentrations in 24 patients treated with continuous intravenous insulin. Levels of 
signiﬁ  cance are indicated for comparison with microdialysate concentrations on the 
day of insulin onset (Wilcoxon signed-rank test).
Notes: *p  0.05, (*)p  0.08.Vascular Health and Risk Management 2008:4(4) 890
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and unfavorable outcome. Further, microdialysis is a regional 
method and the volume of brain tissue monitored by the 
microdialysis catheter covers only a few millimeters from 
the membrane. Some possibly serious effects of insulin on 
blood glucose might not have been detected because of the 
discontinuous blood glucose monitoring. To evaluate whether 
normalization of cerebral glucose levels can improve out-
come in SAH patients, further studies are necessary.
Conclusion
This study conﬁ  rms previous ﬁ  ndings that hyperglycemia is 
a relevant complication in aneurysmal subarachnoid hemor-
rhage. Continuous intravenous insulin treatment over 4 days 
aiming at glucose levels 7.8 mmol/L (140 mg/dL) was 
safe in respect to blood glucose as no hypoglycemia occurred. 
Insulin infusion induced a decrease in cerebral glucose on 
days 1–4 after onset while blood glucose levels and cerebral 
metabolism remained stable except for a reversible increase 
in glycerol indicating a transient metabolic derangement. 
However, to conﬁ  rm the safety of insulin treatment in SAH, 
a larger study population is needed. In any case monitoring 
of blood and cerebral glucose appears to be valuable in SAH 
patients and may help to identify a deterioration of cerebral 
metabolism when insulin starts at critically low cerebral 
glucose levels.
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